HRMY
- Harmony Biosciences Holdings, Inc.
()
Overview
Company Summary
Harmony Biosciences Holdings, Inc. (HRMY) is a pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with sleep and central nervous system disorders. The company's primary focus is on addressing unmet medical needs in the field of sleep medicine.
Harmony Biosciences is committed to improving the lives of patients suffering from disorders such as narcolepsy and idiopathic hypersomnia. Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness, sudden loss of muscle tone (cataplexy), and fragmented nighttime sleep. Idiopathic hypersomnia is a condition where individuals experience excessive sleepiness even with sufficient sleep at night.
The company's flagship product, Wakix� (pitolisant), is a novel medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Wakix works by selectively targeting and stimulating specific histamine receptors in the brain to promote wakefulness.
Harmony Biosciences is also actively engaged in research and development to expand its portfolio of innovative therapies for sleep and central nervous system disorders. The company aims to address the unmet medical needs of patients with sleep-related disorders by leveraging scientific advancements and collaborating with healthcare professionals and patient advocacy groups.
In summary, Harmony Biosciences Holdings, Inc. focuses on developing and commercializing therapies to improve the lives of patients suffering from sleep and central nervous system disorders, primarily narcolepsy and idiopathic hypersomnia. Through their flagship product, Wakix, and ongoing research and development efforts, the company aims to advance the field of sleep medicine and provide effective treatment options for patients in need.